Table 5.
Characteristics of concomitant use of interacting drugs.
| Risk factor | Hip fracture patients (N=17,057) |
Controls (N=85,553) |
|---|---|---|
| N(%) | N(%) | |
| alprazolam and interacting drug use | ||
| pharmacokinetically interacting co-medicationa | 83(0.5) | 535(0.6) |
| pharmacodynamically interacting co-medicationb | 163(1.0) | 554(0.7) |
| pharmacokinetically and pharmacodynamically interacting co-medicationa,b | 221(1.3) | 794(0.9) |
| lorazepam and interacting drug use | ||
| pharmacokinetically interacting co-medicationc | 0(0.0) | 3(0.0) |
| pharmacodynamically interacting co-medicationb | 571(3.4) | 1501(1.8) |
| pharmacokinetically and pharmacodynamically interacting co-medicationb,c | 2(0.0) | 0(0.0) |
| zolpidem and interacting drug use | ||
| pharmacokinetically interacting co-medicationd | 18(0.1) | 90(0.1) |
| pharmacodynamically interacting co-medicationb | 179(1.1) | 480(0.6) |
| pharmacokinetically and pharmacodynamically interacting co-medicationb,d | 20(0.1) | 84(0.1) |
Aprepitant, amiodarone, cimetidine, clarithromycin, cyclosporine, dextropropoxyphen, diltiazem, ergotamine, erythromycin, esomeprazole, fluconazole, fluoxetine, fluvoxamine, indinavir, isoniazid, itraconazole, ketoconazole, nefazodone, nelfinavir, nicardipine, nifedipine, omeprazole, paroxetine, propoxyphene, ritonavir, saquinavir, telithromycin, troleandomycin, and verapamil.
Opioids, H1-antihistamines, barbiturates, anticonvulsants, non-benzodiazepine non-barbiturate hypnotics, antidepressants, neuroleptics, and muscle relaxants.
Valproate and probenecid.
Aprepitant, cimetidine, clarithromycin, diltiazem, erythromycin, fluconazole, indinavir, itraconazole, ketoconazole, nelfinavir, nefazodone, telithromycin, ritonavir, saquinavir, and verapamil.